PT  - JOURNAL ARTICLE
AU  - Li, Rui
AU  - Li, Yan
AU  - Zou, Zhuoru
AU  - Liu, Yiming
AU  - Li, Xinghui
AU  - Zhuang, Guihua
AU  - Shen, Mingwang
AU  - Zhang, Lei
TI  - Projecting the impact of SARS-CoV-2 variants on the COVID-19 epidemic and social restoration in the United States: a mathematical modelling study
AID  - 10.1101/2021.06.24.21259370
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.06.24.21259370
4099  - http://medrxiv.org/content/early/2021/06/26/2021.06.24.21259370.short
4100  - http://medrxiv.org/content/early/2021/06/26/2021.06.24.21259370.full
AB  - Background The SARS-CoV-2 Alpha variant B.1.1.7 became prevalent in the United States (US). We aimed to evaluate the impact of vaccination scale-up and potential reduction in the vaccination effectiveness on the COVID-19 epidemic and social restoration in the US.Methods We extended a published compartmental model and calibrated the model to the latest US COVID-19 data. We estimated the vaccine effectiveness against B.1.1.7 and evaluated the impact of a potential reduction in vaccine effectiveness on future epidemics. We projected the epidemic trends under different levels of social restoration.Results We estimated the overall existing vaccine effectiveness against B.1.1.7 to be 88.5% (95%CI: 87.4-89.5%) and vaccination coverage would reach 70% by the end of August, 2021. With this vaccine effectiveness and coverage, we anticipated 498,972 (109,998-885,947) cumulative infections and 15,443 (3,828-27,057) deaths nationwide over the next 12 months, of which 95.0% infections and 93.3% deaths were caused by B.1.1.7. Complete social restoration at 70% vaccination coverage would only slightly increase cumulative infections and deaths to 511,159 (110,578-911,740) and 15,739 (3,841-27,638), respectively. However, if the vaccine effectiveness were reduced to 75%, 50% or 25% due to new SARS-CoV-2 variants, we predicted 667,075 (130,682-1,203,468), 1.7m (0.2-3.2m), 19.0m (5.3-32.7m) new infections and 19,249 (4,281-34,217), 42,265 (5,081-79,448), 426,860 (117,229-736,490) cumulative deaths to occur over the next 12 months. Further, social restoration at a lower vaccination coverage would lead to even greater future outbreaks.Conclusion Current COVID-19 vaccines remain effective against the B.1.1.7 variant, and 70% vaccination coverage would be sufficient to restore social activities to a pre-pandemic level. Further reduction in vaccine effectiveness against SARS-CoV-2 variants would result in a potential surge of the epidemic in the future.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThe work is supported by the Bill & Melinda Gates Foundation. LZ is supported by the National Natural Science Foundation of China (Grant number: 81950410639); Outstanding Young Scholars Funding (Grant number: 3111500001); Xi'an Jiaotong University Basic Research and Profession Grant (Grant number: xtr022019003 and xzy032020032) and Xi'an Jiaotong University Young Talent Support Grant (Grant number: YX6J004). MS was supported by the National Natural Science Foundation of China (grant number: 11801435), China Postdoctoral Science Foundation (grant number: 2018M631134, 2020T130095ZX); the Fundamental Research Funds for the Central Universities (grant number: xjh012019055); Natural Science Basic Research Program of Shaanxi Province (Grant number: 2019JQ-187); XL was supported by the Special emergency public health safety project of Shaanxi Provincial Education Department (Grant number: 20JG007).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not applicableAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets analyzed during the current study are available in the [Johns Hopkins University Coronavirus Resource Center] repository, [https://coronavirus.jhu.edu]; [Vaccinations in the United States] repository, [https://covid.cdc.gov/covid-data-tracker/#vaccinations.]; [Variant Proportions in the US] repository, [https://covid.cdc.gov/covid-data-tracker/#variant-proportions].